摘要
目的探讨每周1次大剂量促红素(rHuEPO)治疗慢性肾衰贫血的临床疗效、费用经济性和不良反应。方法29例慢性肾衰伴贫血非透析患者随机被分为两组,治疗组:16例,给予rHuEPO9000U皮下注射,每周1次;对照组:13例,给予rHuEPO9000U/周,分3次皮下注射,两组患者治疗间期均为12周,观察治疗期间血常规、血压和不良反应。结果治疗组中显效8例,有效5例,无效3例,总有效率81·3%;对照组中显效7例,有效3例,无效3例,总有效率77·0%。两组比较差异无显著意义。治疗组费用经济性和患者对治疗的依从性好于对照组;两组不良反应的发生差异无显著意义。结论每周1次大剂量rHuEPO皮下注射可显著改善慢性肾衰患者贫血,降低费用,减轻经济负担,提高依从性,是一种有效、经济、安全的治疗方式。
Objective To evaluate and compare the clinical effects,cost and safety of recombinant human erythropoietin（rHu EPO） between once weekly and twice weekly for anemia in chronic renal failure patients. Methotis 29 chronic renal failure patients were randomly divided into 2 groups. 16 patients in the treatment group accepted 9000U rHu EPO once a week subcutaneously and 13 patients in the control group accepted 3000U rHu EPO twice a week through subcutaneous injection for 12 weeks. Blood routine, blood pressure and side effects were observed. Results The obvious effective, effective, ineffective and clinical efficiency ratio in the treatment group were 8,5,3,81.3 % respectively, and 7,3,3,77.0 % in the control group respectively. No significant difference was found in 2 groups. Therapeutic cost and compliance in the treatment group were better than those in control group. Side effects showed no statistical difference in 2 groups. Conclusion High-dosage rHu EPO once a week subcutaneously can improve significantly anemia, lower cost, lighten economical pressure and increase compliance in chronic renal failure patients. It is an effective, economical and safety therapeutic method.
出处
《中国基层医药》
CAS
2005年第8期977-978,共2页
Chinese Journal of Primary Medicine and Pharmacy
